MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
11.94
+0.70
+6.23%
After Hours: 11.99 +0.05 +0.42% 19:55 08/07 EDT
OPEN
11.88
PREV CLOSE
11.24
HIGH
12.08
LOW
11.47
VOLUME
4.94M
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
7.95
MARKET CAP
1.67B
P/E (TTM)
-3.5573
1D
5D
1M
3M
1Y
5Y
1D
Intellia, Roku Trend with Analysts: What Investors Should Know
TipRanks · 2d ago
Analyst Maintains Buy on Intellia as Lonvo-z Progress and Strong Cash Runway Support Unchanged $49 Price Target
TipRanks · 2d ago
Intellia Therapeutics Raised to Outperform From In-Line by Evercore ISI Group
Dow Jones · 3d ago
Intellia Therapeutics Price Target Raised to $24.00/Share From $16.00 by Evercore ISI Group
Dow Jones · 3d ago
Intellia upgraded at Evercore ISI on nex-z hypothesis
Seeking Alpha · 3d ago
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24
Benzinga · 3d ago
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
TipRanks · 3d ago
RBC Capital Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)
TipRanks · 3d ago
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.